The PBS subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Treatment with idelalisib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.
Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.
Make all applications for initial authority approval to prescribe idelalisib for the treatment of follicular B-cell non-Hodgkin’s lymphoma in writing and:
- upload through Health Professional Online Services, or
- post to the PBS Complex Drugs Programs address
All applications for idelalisib must include a completed:
- authority prescription form, and
- Refractory follicular B-cell non-Hodgkin’s lymphoma – idelalisib - Initial PBS authority application form (PB198)
Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.
For more information contact the PBS Complex Drugs Programs enquiry line.